Skip to main content
. 2023 Jul 14;12(14):4671. doi: 10.3390/jcm12144671

Figure 2.

Figure 2

Evolution of visual acuity in the first and last 15 reported eyes from baseline (beginning of brolucizumab treatment) until end of follow up. Circles: Datapoints for the first 15 reported eyes; Triangles: Datapoints for the last 15 reported eyes; *: significant difference between the first 15 and the last 15 (p = 0.03).